Reply: An Incomplete Story
We thank Dr. Reiffel for his interest in our paper (1) . Beta-blockers reduced mortality in landmark, placebo-controlled trials of heart failure with a reduced left ventricular ejection fraction only for those in sinus rhythm rather than atrial fibrillation (AF), despite use of similar beta-blocker formulations and doses (84% of target) and similar heart rate reductions (1) . For patients in AF, neither baseline nor follow-up ventricular rate was associated with beta-blocker benefit, nor have trials comparing rate control intensity shown important differences in outcome, although slower rates may be associated with a worse prognosis for patients with heart failure (2).
Physiologically, slowing heart rate increases pulse and systolic blood pressures. Multivariable analyses investigating interactions amongst heart rate, rhythm, and beta-blockers were adjusted for systolic pressure. AF with ventricular rate <70 beats/min was associated with a 6 mm Hg higher systolic pressure than when >90 beats/min but higher pressure was not associated with a better prognosis.
Data on individual angiotensin-converting-enzyme inhibitors or angiotensinreceptor blockers or their doses were not collected but the proportion prescribed (about 95%) these was similar regardless of heart rhythm. Analyses correcting for use of mineralocorticoid antagonists and digoxin did not affect our conclusions (see Online Table 3 in [1] ).
Observational studies of digoxin are prone to prescribing and other biases, even when propensity-adjusted, and should not be used to assess treatment responses. Randomized trials show no impact of digoxin on mortality in sinus rhythm but do show reductions in hospitalization (3) . Prospective trials of cardiac glycosides in patients with AF are underway (4).
